TJ
Therapeutic Areas
Pyxis Oncology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Micvotabart pelidotin (MICVO, formerly PYX-201) | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) - 2L+ Post Platinum & anti-PD(L)-1 | Phase 1 |
| Micvotabart pelidotin (MICVO) + KEYTRUDA® (pembrolizumab) | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) - 2L+ Post EGFRi and/or anti-PD(L)-1 | Phase 1 |
| Micvotabart pelidotin (MICVO) | Various Solid Tumors | Phase 1 |
Leadership Team at Pyxis Oncology
TC
Thomas Civik
Interim Chief Executive Officer and Board Director
BB
Balu Balasubramanian
Interim Chief Technology Officer
MB
Michael Bui
Head of Global Regulatory
CC
Chris Cohen
Head of Drug Safety and Pharmacovigilance
MC
Marsha Crochiere
Head of Translational Medicine and Research
TD
Tom Dorney
Head of Corporate Strategy & Finance
BF
Brian Freeman
SVP, Global Program Leader
SH
Shui He
Head of Biometrics
AK
Alex Kane
SVP, Investor Relations & Capital Markets
HK
Heather Knowles
SVP, Head of Global Clinical Operations